Dr. Joseph Quinn, a prominent professor at Oregon Health & Science University, dives into the groundbreaking world of fluid biomarkers for dementia diagnosis. He discusses the pivotal role of cerebrospinal fluid in clinical practice and the evolving landscape of blood tests for Alzheimer's. Quinn highlights critical trials on plasma neurofilament light and GFAP, exploring their potential in tracking treatment efficacy. The conversation also touches on exciting developments and the need for precise diagnostics to enhance early treatment strategies for neurodegenerative diseases.